Category Archives: Human Longevity

A new research has revealed the whole-genome sequences of the world's oldest living people.

The researchers performed whole-genome sequencing on 17 supercentenarians to explore the genetic basis underlying extreme human longevity.

Supercentenarians are the world's oldest people, living beyond 110 years of age. Seventy-four are alive worldwide, with twenty-two living in the United States.

Researchers found out that one supercentenarian carries a variant associated with a heart condition, which had little or no effect on his/her health, as this person lived over 110 years. The authors added that it is recommended by the American College of Medical Genetics and Genomics to report the results to this individual as an incidental finding.

Authors didn't find significant association with extreme longevity, the authors have publicly published the genomes, making them available as a resource for future studies on the genetic basis of extreme longevity.

The study is published in the open-access journal PLOS ONE.

(Posted on 13-11-2014)

Post your comments

Information on States of India:

Andaman Nicobar | Andhra Pradesh | Arunachal Pradesh | Assam | Bihar | Chandigarh | Chhattisgarh | Dadar Nagar Haveli | Daman Diu | Delhi | Goa | Gujarat | Haryana | Himachal Pradesh | Jammu Kashmir | Jharkhand | Karnataka | Kerala | Lakshadweep | Madhya Pradesh | Maharashtra | Manipur | Meghalaya | Mizoram | Nagaland | Orissa | Pondicherry | Punjab | Rajasthan | Sikkim | Tamil Nadu | Tripura | Uttar Pradesh | Uttaranchal | West Bengal

Read the original post:
World's oldest living people's gene has no longevity secrets

Published November 13, 2014

Whats the secret to living a long life? After four years of exploring just that, a team of geneticists at Stanford University have found the answer is more elusive than one might think, reported SFGate.com.

We were looking for a really simple explanation in a single gene, study author Stuart K. Kim, a Stanford geneticist and molecular biologist, told SFGate.com. And we know now that its a lot more complicated, and it will take a lot more experiments and a lot more data from the genes of more supercentenarians to find out just what might account for their ages.

Kim and a team of scientists at Stanford studied the genes of 17 supercentarians, or people who lived to the age 110 and beyond. After four years of studying an estimated 21,000 human genes, they could not find a gene or group of genes that were linked to the study participants long life span.

In the study, published Wednesday in the journal PLOS One, the researchers compared the genes of 17 supercententenarians and those of 4,300 normal subjects recorded earlier in a National Institutes of Health (NIH) study. They used a technology called whole-genome sequencing to identify genes linked with disease, immunity, and others whose functions are unclear.

None of the 17 supercentenarians in the study is alive. Their ages ranged from 100 to 116, and the study authors confirmed their life spans by referencing official documents such as birth certificates and passports, Kim told SFGate.com.

A vast majority of the supercentenarians appeared to be exempt from age-related disease at the time of their death. Only one of the subjects, who had Alzheimers disease, was not. One subject worked as a pediatrician until age 103 and died at age 114, while another drove a car until the age of 107.

As would be expected, Kim told SFGate.com, supercentenarians have escaped many age-related diseases, and their rates of cancer and heart disease and stroke are not significantly different from the general population.

The researchers found that the family members of the centenarians also have a longer than average life span, despite the fact that their lifestyle choices like smoking and diet arent especially different when compared with the habits of ordinary people.

Taken together, Kim told SFGate.com, these findings provide ample evidence that extreme longevity has a genetic component.

See more here:
Stanford University scientists still searching for longevity gene in humans

PUBLIC RELEASE DATE:

12-Nov-2014

Contact: Kayla Graham onepress@plos.org PLOS

Using fewer than twenty genomes, researchers were unable to find rare protein-altering variants significantly associated with extreme longevity, according to a study published November 12, 2014 in the open-access journal PLOS ONE by Hinco Gierman from Stanford University and colleagues.

Supercentenarians are the world's oldest people, living beyond 110 years of age. Seventy-four are alive worldwide, with twenty-two living in the United States. The authors of this study performed whole-genome sequencing on 17 supercentenarians to explore the genetic basis underlying extreme human longevity.

From this small sample size, the researchers were unable to find rare protein-altering variants significantly associated with extreme longevity compared to control genomes. However, they did find that one supercentenarian carries a variant associated with a heart condition, which had little or no effect on his/her health, as this person lived over 110 years. The authors added that it is recommended by the American College of Medical Genetics and Genomics to report the results to this individual as an incidental finding. Although the authors didn't find significant association with extreme longevity, the authors have publicly published the genomes, making them available as a resource for future studies on the genetic basis of extreme longevity.

###

In your coverage please use this URL to provide access to the freely available paper: http://dx.plos.org/10.1371/journal.pone.0112430

Citation: Gierman HJ, Fortney K, Roach JC, Coles NS, Li H, et al. (2014) Whole-Genome Sequencing of the World's Oldest People. PLoS ONE 9(11): e112430. doi:10.1371/journal.pone.0112430

Funding: This work was supported by the Ellison Medical Foundation/American Federation for Aging Research Fellowship, Stanford Dean's Fellowship, The Paul Glenn Foundation Biology of Aging Seed Grant, National Institute of General Medical Sciences Center for Systems Biology (P50 GM076547) and the University of Luxembourg - Institute for Systems Biology Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Originally posted here:
The whole-genome sequences of the world's oldest living people published

The other types of shares are biotech and medical device firms that are coming up with new drugs and inventions. A company we really like at the moment is Esperion, which has invented a drug that lowers cholesterol.

Another is Endologix, which has invented a product for a really nasty condition called an aortic aneurysm, which is essentially where a big blood vessel in a persons chest can pop. The firm has come up with a product that can stop this from happening and keep people alive for an extra 20 to 30 years.

But Mr Mahony said investing in drug companies did not come without risk. Most drugs fail in clinical trails, so there is a lot of clinical development risk, he said.

The other main threats that can sour investor sentiment towards health care shares is regulatory and political meddling.

We try and avoid parts of the market where regulation is changing rapidly, so at the moment with the massive period of US health care reform we are avoiding certain areas like nursing homes and rehabilitation care, because a lot of change is taking place.

Fund experts warn that backing health care was not an easy ride as the sector has a tendency to quickly fall in and out of fashion. For this reason it is best to invest for a lengthy period, especially to capture profit from themes such as ageing populations.

Russ Mould of AJ Bell Youinvest, the fund shop, said investors should be willing to buy and hold one of these specialist funds for at least 10 years.

Mr Mould said the Polar Capital fund was one of his favourites, but the fund charge was high and a performance fee could also be applied, which would eat into investors returns.

The fund consistently beats peers and has served investors well. The only downside is the fund charge, which is higher than other funds that invest in health care, but arguably its superior performance is worth paying extra for, he said.

Mr Mould said the other fund he rates as a buy is the Worldwide Healthcare Trust. The fund manager Samuel Isaly has been investing in global healthcare shares since the late Sixties and he regularly turns his experiences into strong outperformance.

Read more here:
'I've made a fortune from healthcare shares - here are my share tips'

Download Human Longevity PDF
Click Here To Download Human Longevity http://bit.ly/1rQgWn1.

By: Lazaro C. Magee

See the original post:
Download Human Longevity PDF - Video

Scientists at the University of Texas are developing the breathable vaccine It has been shown to protect monkeys against the deadly virus Next step is to test vaccine on humans in phase one clinical trials Researcherssaidrespiratoryvaccine could overcome logistical problems of storing,transporting and administeringinjectablevaccines

By Lizzie Parry for MailOnline

Published: 08:47 EST, 4 November 2014 | Updated: 13:27 EST, 4 November 2014

305 shares

8

View comments

A nasal spray being developed as a potential vaccine for the deadly Ebola virus has been found to be effective.

Scientists at the University of Texas discovered the breathable vaccine offers long-term protection during pre-clinical trials with monkeys.

Since the current outbreak erupted in West Africa earlier this year, almost 5,000 people have lost their lives - the majority in Sierra Leone, Liberia and Guinea.

A number of injectable experimental vaccines are being trialled in the US, UK and Mali, with plans to extend human trials into other parts of Europe, Gabon and Kenya.

View post:
Ebola nasal spray vaccine found to 'offer long-term protection'

We need more women in technology. In 2012, women made up only 26 percent of the computing workforce, out of 3,816,000 computing-related occupations. (Department of Labor Current Population Survey, 2012)

In the same year, only 18 percent of computer science majors were women.

Women hold only 11 percent of executive technical roles at privately held, venture-backed companies. (Dow Jones VentureSource, 2012)

Only 7 percent of venture capital goes to women-owned businesses, and of those venture capitalists investing in startups, only 4.2 percent are women.

These and other telling statistics are indicative of a huge problem!

Its time for a shift

I have had the extraordinary privilege of working with some of the most inspiring, ambitious female leaders of our time.

I want to devote this blog to them.

Women are primed to lead in this new era of innovation.

Im proud that each years Singularity University Graduate program has some 40 percent women attendees.

Read more here:
Why We Need More Women In Technology

LA JOLLA, Californie, 2 novembre 2014 /PRNewswire/ -- Human Longevity Inc. (HLI), une socit spcialise en technologies de la sant humaine bases sur les donnes biologiques, et en thrapie cellulaire, a annonc aujourd'hui l'arrive de Dr Barry Merriman en tant que vice-prsident de Global Technology Assessment (Evaluation des Technologies mondiales) et de PaulMola(MS - Master en Science) en tant que directeur de Global Solutions (Solutions mondiales). Tous deux travailleront ensemble au sein de la nouvelle Global Solutions Initiative (Initiative de Solutions mondiales) de HLI afin de chercher de nouvelles opportunits commerciales stratgiques dans le monde entier.

Logo - http://photos.prnewswire.com/prnh/20140304/LA76169LOGO

La Global Solutions Initiative de HLI a pour but de faciliter les partenariats commerciaux avec une varit de clients tels que les gouvernements trangers, les grands systmes de sant nationaux, et les ONG ddies la sant et aux maladies d'importancemondiale, intresss d'entreprendre des initiatives gnomiques l'chelle des populations ainsi que des initiatives mdicales personnalises. Dr Merriman et M Mola collaboreront avec ces entits afin d'offrir des solutions d'entreprise, ainsi que des services et opportunits commerciales sur mesure pour renforcer et acclrer ces projets. Ceci comprend l'accs la base de donnes biologique humaine complte de HLI, associe sa propre infrastructure informatique et ses solutions logicielles analytiques.

Nous nous rjouissons d'accueillir au sein de l'quipe de HLI Barry et Paul qui apportent une expertise unique et varie aussi bien scientifique que technologique et commerciale , a dclar Dr J. Craig Venter, co-fondateur et prsident-directeur gnral de HLI. Leur connaissance du march gnomique mondial, associe leur solide exprience scientifique et technologique et leur capacit traduire cette exprience en partenariats fructueux l'chelle internationale sera inestimable pour HLI .

Dr Merriman a comment, Mon but a toujours t d'utiliser la science et la technologie pour faire avancer la sant et la longvit humaine. HLI est unique du fait qu'elle a une approche complte et intgre de la question, combinant une dmarche focalise, des ressources et une chelle essentielle pour russir, tout en ayant en ligne de mire une vritable rvolution des soins de sant. Je suis enthousiaste l'ide de travailler avec des leaders l'chelle internationale sur la faon dont HLI pourra soutenir leurs efforts pour amliorer la sant et soigner la maladie au sein de leurs populations .

M Mola a ajout, L'investissement cibl de HLI au profit d'une infrastructure de bout en bout ingale ddie aux projets l'chelle des populations viendra en renfort des capacits cliniques les plus avances pour rsoudre certaines des maladies communes lies au vieillissement. Je suis heureux de rejoindre HLI et suis impatient d'aider la socit raliser sa mission d'intgration complte des avances gnomiques, thrapies cellulaires et technologies de l'information de la sant, afin de crer une base de connaissances sans prcdent sur les donnes biologiques des patients pour produire un changement des soins de sant l'chelle mondiale .

Avant de rejoindre HLI, Dr Merriman tait chez Life Technologies (maintenant une division de Thermo Fisher Scientific Inc.), o il tait l'architecte du systme principal pour la technologie avance de squenage de l'ADN, ainsi que le co-fondateur et le chef de la scurit du groupe Enterprise Genomics Solutions (Solutions gnomiques d'entreprise). Dans ces fonctions, il a tabli et guid la stratgique globale de la socit ainsi que son portefeuille en technologie de squenage, et conu des projets gnomiques l'chelle nationale. Auparavant, Dr Merriman a fait partie durant 20 ans de la facult de l'UCLA (Universit de Californie Los Angeles) o il dirigeait les travaux de recherche multidisciplinaires en gntique humaine, technologies gnomique, ainsi qu'en mathmatiques, physique et ingnierie. Dr Merriman a un doctorat (PhD) en Mathmatiques appliques de l'Universit de Chicago.

Paul Mola (MS, MSEL - Master of Science in Executive Leadership), arrive aussi chez HLI de Life Technologies, o il tait directeur de la stratgie et directeur du personnel pour la division Genetic Systems (Systmes gntiques). Il y fonda notamment leur groupe Enterprise Genomics Solutions (Solutions gnomiques d'entreprise) qui tablit le modle commercial pour des projets de recherche gnomique translationnelle l'chelle nationale, dont leur premire initiative phare internationale, le Projet du gnome humain saoudien en Arabie Saoudite. Avant cela, Mola a exerc des fonctions dans le dveloppement de produits et la commercialisation chez Applied Biosystems et Roche Diagnostics.Mola a obtenu unMaster en Biotechnologies (MS) de l'Universit de Sciences et Technologies de Cochin et unMaster en Leadership de l'Ecole de Commerce de l'Universit de San Diego.

propos de Human Longevity Inc.HLI, une socit prive ayant son sige San Diego, en Californie, a t fonde en 2013 par des pionniers des secteurs de la gnomique et de la thrapie fonde sur les cellules souches. Utilisant les avances en matire de squenage gnomique, de microbiome humain, de protomique, d'informatique, de calcul et de technologies de thrapie cellulaire, HLI met en place la base de donnes la plus complte au monde sur les gnotypes et phnotypes humains qui constituera la base de tout un ventail d'opportunits de commercialisation pour aider rsoudre les maladies lies au vieillissement et au dclin biologique humain. HLI octroiera des licences pour accder sa base de donnes et dveloppera de nouveaux moyens diagnostiques et thrapeutiques dans le cadre de son offre de produits. Pour de plus amples informations, veuillez consulter le site http://www.humanlongevity.com

SOURCE Human Longevity, Inc.

See the original post:
Human Longevity Inc. recrute les experts Barry Merriman (PhD) et Paul Mola (MS) pour diriger leur nouvelle Initiative ...

LA JOLLA, Kalifornien, 1. November 2014 /PRNewswire/ -- Human Longevity, Inc. (HLI), ein mit biologischen Daten gesttztes Unternehmen im Bereich der menschlichen Gesundheitstechnologie und Zelltherapie, hat heute die Berufungen von Barry Merriman, Ph.D. zum Vice President of Global Technology Assessmentund Paul Mola, M.S. zum Head of Global Solutions bekannt gegeben. Beide werden zusammen an der neuen Global Solutions Initiative von HLI zur Identifizierung neuer, weltweiter strategischer Geschftsmglichkeiten arbeiten.

Logo - http://photos.prnewswire.com/prnh/20140304/LA76169LOGO

Die Global Solutions Initiative von HLI ist auf geschftliche Partnerschaften mit einer Vielzahl von verschiedenen Kunden ausgerichtet, darunter Regierungen aus dem Ausland, groe nationale Gesundheitssysteme sowie globale Wohlfahrtsorganisationen mit Schwerpunkt auf den Themen Krankheit oder Gesundheit, die interessiert an der Durchfhrung von Initiativen zu Genomik und personalisierter Medizin im Bevlkerungsmastab sind. Dr. Merriman und Mr. Mola werden sich mit diesen Einrichtungen dafr engagieren, solche Projekte durch auf sie zugeschnittene Unternehmenslsungen und Dienstleistungen und Geschftsmglichkeiten zu strken und zu beschleunigen. Dies beinhaltet den Zugang zur umfassenden humanbiologischen Datenbank von HLI, zusammen mit der unternehmenseigenen Computerinfrastruktur und analytischen Software.

"Wir freuen uns, Barry und Paul im Team von HLI willkommen heien zu knnen, denn sie bringen eine einzigartige und vielfltige wissenschaftliche, technologische und geschftliche Expertise mit," erklrte J. Craig Venter, PhD, Mitgrnder von HLI, Chairman und Chief Executive Officer. "Ihre Kenntnis des globalen Genomikmarktes, zusammen mit ihren umfangreichen wissenschaftlichen und technologischen Backgrounds und der Fhigkeit, diesen Erfahrungsschatz in erfolgreiche globale Partnerschaften zu berfhren, wird sich als unschtzbar wertvoll fr HLI erweisen."

Dr. Merriman kommentierte, "Mein Ziel war immer, Wissenschaft und Technologie zum Fortschritt fr die Gesundheit und Langlebigkeit von Menschen einzusetzen. HLI verfolgt dabei einen vollstndigen und integrierten Ansatz, der einzigartig ist und ber den Fokus, die Ressourcen und die Grenordnung, die zum Erfolg notwendig sind, verfgt. Am Endpunkt steht eine echte Revolutionierung im Gesundheitswesen. Ich bin begeistert darber, mit fhrenden Krften auf globaler Ebene gemeinsam Wege, ber die HLI zu ihren Bemhungen fr die Verbesserung der Gesundheit und Lsung von Krankheit in ihren Bevlkerungen beitrgt, erarbeiten zu knnen."

Mr. Mola fgte hinzu, "Das fokussierte Investment von HLI zur Schaffung einer unerreichten, lckenlosen Infrastruktur fr Projekte im Bevlkerungsmastab wird die fortschrittlichsten klinischen Mglichkeiten zur Lsung einiger der hufigsten altersbedingten Erkrankungen aktivieren. Ich freue mich, zu HLI zu kommen und bin bestrebt, dem Unternehmen bei der Umsetzung seiner Mission der umfassenden Integration von Fortschritten in der Genomik, zellulren Therapeutika und Gesundheitsinformationstechnologie zur Schaffung einer bisher nie dagewesenen Wissensgrundlage von patientenbezogenen biologischen Daten zu helfen, um einen Wandel im Gesundheitswesen auf globaler Ebene zu bewirken."

Dr. Merriman war vor seiner Berufung zu HLI bei Life Technologies (inzwischen ein Unternehmensbereich von Thermo Fisher Scientific, Inc.) ttig, wo er zuletzt Lead System Architect fr Advanced DNA Sequencing Technology und Mitgrnder und CSO der Enterprise Genomics Solutions Group war. In diesen Funktionen etablierte und begleitete er die Gesamtstrategie des Unternehmens und das Portfolio in der Sequenzierungstechnik und entwickelte Genomik-Projekte auf nationaler Ebene. Vorhergehend war Dr. Merriman fr 20 Jahre an der Fakultt der UCLA ttig, wo er interdisziplinre Forschungsarbeiten in Humangenetik, genomischer Technologie, sowie Mathematik, Physik und Ingenieurwissenschaft leitete. Dr. Merriman hlt einen Ph.D. in angewandter Mathematik, verliehen von der University of Chicago.

Paul Mola, M.S., MSEL, war vor seiner Berufung zu HLI ebenfalls bei Life Technologies ttig als Head of Strategy und Chief of Staff fr die Genetic Systems Division. Dort grndete er die Enterprise Genomics Solutions Group, die das Geschftsmodell fr die Untersttzung translationaler Genomik-Projekte auf nationaler Ebene etablierte, darunter die erste globale Leitinitiative, das Saudi Human Genome Project in Saudi-Arabien. Mola hatte zuvor Rollen in Produktentwicklung und kommerziellen Funktionen bei Applied Biosystems und Roche Diagnostics inne. Mola erlangte seinen M.S. in Biotechnologie an der Cochin University of Science and Technology und seinen MSEL an der University of San Diego, School of Business.

Informationen zu Human Longevity, Inc.HLI ist ein in privater Hand gehaltenes Unternehmen mit Hauptniederlassung in San Diego, Kalifornien, und wurde 2013 von Pionieren auf dem Gebiet der Genomik und der Stammzellentherapie gegrndet. HLI baut durch die Nutzung der technologischen Fortschritte in der Genomsequenzierung, dem Humanmikrobiom, der Proteomik, der Informatik, der Computertechnik und der Zelltherapie die weltweit umfangreichste Datenbank an Humangenotypen und -phnotypen als Basis fr verschiedene Kommerzialisierungsmglichkeiten auf, um alterungsbedingten Erkrankungen und dem biologischen Verfall des Menschen entgegenzuwirken. HLI wird den Zugriff auf seine Datenbank lizenzieren und als Teil seines Produktangebots neue Diagnose- und Therapieverfahren entwickeln. Weitere Informationen finden Sie unter http://www.humanlongevity.com

Read more here:
Human Longevity, Inc. beruft die Branchenexperten Barry Merriman, Ph.D. und Paul Mola, M.S. zur Leitung der neuen ...

LA JOLLA, California, Oct. 31, 2014 /PRNewswire/ -- Human Longevity, Inc. (HLI), a biological data-driven human health technology and cell therapy company, today announced the addition of Barry Merriman, Ph.D., as Vice President of Global Technology Assessmentand Paul Mola, M.S. as Head of Global Solutions. The two will work together in HLI's new Global Solutions Initiative to seek strategic business opportunities worldwide.

Logo - http://photos.prnewswire.com/prnh/20140304/LA76169LOGO

HLI's Global Solutions Initiative is aimed at business partnerships with a variety of customers including foreign governments, large national healthcare systems, and global disease or health-focused charities interested in undertaking population-scale genomic and personalized medicine initiatives. Dr. Merriman and Mr. Mola will engage with these entities to offer enterprise solutions, and services and business opportunities customized to empower and accelerate these projects. This includes access to HLI's comprehensive human biological database, coupled with the company's proprietary computational infrastructure and analytical software solutions.

"We are pleased to welcome Barry and Paul to the HLI team as they bring unique and varied scientific, technological and business expertise," said J. Craig Venter, PhD, HLI's Co-founder, Chairman, and Chief Executive Officer. "Their knowledge of the global genomics market, coupled with their strong scientific and technology backgrounds and ability to translate this experience into successful global partnerships will be invaluable to HLI."

Dr. Merriman commented, "My goal has always been to use science and technology to advance human health and longevity. HLI is unique in pursuing a complete and integrated approach to this, with the focus, resources and scale required for success, and with an endpoint of truly revolutionizing health care. I am very excited to work with leaders globally on ways for HLI to empower their efforts to improve health and solve disease in their populations."

Mr. Mola added, "HLI's focused investment to create an unmatched, end-to-end infrastructure for population scale projects will enable the most advanced clinical capabilities for solving some of the common diseases of aging. I am pleased to be joining HLI and am eager to help the company realize its mission of comprehensive integration of genomic advances, cellular therapeutics, and health information technology, to create an unprecedented knowledge base of patient biological data to effect health care change on a global scale."

Dr. Merriman comes to HLI most recently from Life Technologies (now a Division of Thermo Fisher Scientific, Inc.), where he was the Lead System Architect for Advanced DNA Sequencing Technology, and co-founder and CSO of the Enterprise Genomics Solutions group. In these roles he established and guided the company's overall strategy and portfolio in sequencing technology, and architected national scale genomics projects. Prior to this, Dr. Merriman was on the faculty of UCLA for 20 years, where he led interdisciplinary research efforts in human genetics, genomic technology, as well as math, physics and engineering. Dr. Merriman has a Ph.D. in Applied Math from The University of Chicago.

Paul Mola, M.S., MSEL, also comes to HLI from Life Technologies, where he was Head of Strategy and Chief of Staff for their Genetic Systems Division. There, he founded their Enterprise Genomics Solutions Group, which established the business model for supporting national scale translational genomics projects, including their first global flagship initiative, the Saudi Human Genome Project in Saudi Arabia. Mola previously served in product development and commercial capacities at Applied Biosystems and Roche Diagnostics. Mola earned an M.S. in Biotechnology from Cochin University of Science and Technology and a MSEL from the University of San Diego, School of Business.

About Human Longevity, Inc.HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world's most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit, http://www.humanlongevity.com

Read more from the original source:
Human Longevity, Inc. Hires Industry Experts Barry Merriman, Ph.D., and Paul Mola, M.S. to Lead New Global Solutions ...